Oukeya

Oukeya is a clinical-stage biotechnology company headquartered in Beijing, China, dedicated to the development of next-generation gene therapies. The company utilizes a proprietary adeno-associated virus (AAV) platform to engineer treatments for chronic and degenerative diseases, particularly in the fields of ophthalmology and neurology. Its lead program, OKY-001, is an AAV-delivered anti-VEGF therapy currently in clinical trials for wet age-related macular degeneration (nAMD) and diabetic macular edema (DME). By enabling the eye to produce its own therapeutic proteins, Oukeya's approach aims to eliminate the need for frequent intraocular injections, significantly improving patient compliance and outcomes. The company is supported by leading venture capital investors and is actively expanding its technological capabilities in vector design and manufacturing.